Pachymeningitis With Dural Vessel Dilatation in MOG Antibody–Associated Disease: A Case Report

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a novel inflammatory demyelinating disorder marked by heterogenous clinical and radiological manifestations. Pachymeningitis is a rare manifestation. An 18-year-old male was hospitalized with fever, dizziness, altered c...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in neurological medicine Vol. 2025; no. 1; p. 5686302
Main Authors: Huang, Yunchen, Song, Yafei, Liu, Ding, Liu, Yin
Format: Journal Article
Language:English
Published: United States John Wiley & Sons, Inc 01.01.2025
Wiley
Subjects:
Antibodies
Blood
Bone marrow
Case reports
Cellular biology
Cerebrospinal fluid
Consciousness
Convulsions & seizures
Diagnostic tests
Disease
Diseases
Encephalitis
Glycoproteins
Hypotension
Leukocytes
Levetiracetam
Magnetic resonance imaging
Meningitis
Myelin proteins
Nervous system
Neutrophils
Seizures (Medicine)
Viral antibodies
seizure
dural
myelin oligodendrocyte glycoprotein
meningitis
ISSN:2090-6668, 2090-6676
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a novel inflammatory demyelinating disorder marked by heterogenous clinical and radiological manifestations. Pachymeningitis is a rare manifestation. An 18-year-old male was hospitalized with fever, dizziness, altered consciousness, and seizure attacks. Serum testing was positive for MOG antibodies. Diffuse pachymeningitis with prominent dural vessel dilation was observed prior to treatment, which markedly improved after hormone therapy. MOGAD pachymeningitis with dural vessel dilatation broadens the imaging spectrum of MOGAD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2090-6668
2090-6676
DOI:10.1155/crnm/5686302